Uncategorized
Valeant quarterly revenue totals $1.54 billion
Valeant Pharmaceuticals reported $1.54 billion in total revenue for the third quarter, a 74% increase from the same period in 2012, according to a press release.Product sales totaled $1.5 billion, up from $852.7 million in the same period in 2012.Developed markets revenue totaled $1.14 billion, a 77% increase from the third quarter 2012, mainly attributed to the acquisition of Bausch + Lomb.